These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 18953083

  • 1. A population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophrenia.
    Cooper D, Moisan J, Abdous B, Grégoire JP.
    Can J Clin Pharmacol; 2008; 15(3):e385-97. PubMed ID: 18953083
    [Abstract] [Full Text] [Related]

  • 2. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [Abstract] [Full Text] [Related]

  • 3. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
    Mladsi DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT.
    Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
    [Abstract] [Full Text] [Related]

  • 4. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
    Bounthavong M, Okamoto MP.
    J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814
    [Abstract] [Full Text] [Related]

  • 5. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
    Taylor DM, Wright T, Libretto SE, Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS) U.K. Investigator Group.
    J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
    [Abstract] [Full Text] [Related]

  • 6. Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia.
    Zhao Z.
    Curr Med Res Opin; 2004 Jul; 20(7):1039-48. PubMed ID: 15265249
    [Abstract] [Full Text] [Related]

  • 7. Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.
    Yu W, Ren XS, Lee AF, Herz L, Huang YH, Kazis LE.
    Pharmacoeconomics; 2006 Jul; 24(12):1233-48. PubMed ID: 17129077
    [Abstract] [Full Text] [Related]

  • 8. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
    Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL.
    Value Health; 2004 Jul; 7(1):22-35. PubMed ID: 14720128
    [Abstract] [Full Text] [Related]

  • 9. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
    Yang YK, Tarn YH, Wang TY, Liu CY, Laio YC, Chou YH, Lee SM, Chen CC.
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
    [Abstract] [Full Text] [Related]

  • 10. A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
    Lubinga SJ, Mutamba BB, Nganizi A, Babigumira JB.
    Appl Health Econ Health Policy; 2015 Oct; 13(5):493-506. PubMed ID: 25958192
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of olanzapine and risperidone in Norway.
    Kim K, Aas E.
    J Ment Health Policy Econ; 2011 Sep; 14(3):125-35. PubMed ID: 22116170
    [Abstract] [Full Text] [Related]

  • 12. Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database.
    Zhao Z, Namjoshi M, Barber BL, Loosbrock DL, Tunis SL, Zhu B, Breier A.
    CNS Drugs; 2004 Sep; 18(3):157-64. PubMed ID: 14871159
    [Abstract] [Full Text] [Related]

  • 13. Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis.
    Law WL, Hui HY, Young WM, You JH.
    Int J Clin Pharmacol Ther; 2007 May; 45(5):264-70. PubMed ID: 17542348
    [Abstract] [Full Text] [Related]

  • 14. Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis.
    Lucey JV, Libretto SE.
    Ir J Med Sci; 2003 May; 172(4):195-201. PubMed ID: 15029989
    [Abstract] [Full Text] [Related]

  • 15. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine.
    Gianfrancesco F, Pesa J, Wang RH.
    J Manag Care Pharm; 2005 Apr; 11(3):220-30. PubMed ID: 15804206
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.
    Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R.
    Value Health; 2006 Apr; 9(2):77-89. PubMed ID: 16626411
    [Abstract] [Full Text] [Related]

  • 17. Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
    Zhu B, Ascher-Svanum H, Faries DE, Correll CU, Kane JM.
    BMC Psychiatry; 2008 Apr 04; 8():19. PubMed ID: 18394168
    [Abstract] [Full Text] [Related]

  • 18. Cost evaluation of risperidone compared with olanzapine.
    Byerly MJ, Weber M, Brooks D, Casey SB, Elliot S, Hawkins J.
    Psychiatr Serv; 2003 May 04; 54(5):742-4. PubMed ID: 12719509
    [Abstract] [Full Text] [Related]

  • 19. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.
    Moisan J, Grégoire JP.
    Clin Ther; 2010 May 04; 32 Suppl 1():S21-31. PubMed ID: 20152549
    [Abstract] [Full Text] [Related]

  • 20. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
    Kongsakon R, Leelahanaj T, Price N, Birinyi-Strachan L, Davey P.
    J Med Assoc Thai; 2005 Sep 04; 88(9):1267-77. PubMed ID: 16536115
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.